Delinia Obtains $35,000,000 Series A Funding

  • Feed Type
  • Date
    9/15/2016
  • Company Name
    Delinia
  • Mailing Address
    953 Indiana Street San Francisco, CA 94107 USA
  • Company Description
    Delinia is a biotechnology company developing novel therapeutics for the treatment of autoimmune diseases. Delinia’s lead program is a molecule that potentiates and expands Regulatory T Cells (Tregs), powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis.
  • Website
    http://www.deliniabio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $35,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Delinia plans to use the capital raised through this financing to advance the lead program though clinical proof-of-concept.
  • M&A Terms
  • Venture Investor
    Sofinnova Ventures
  • Venture Investor
    Atlas Accelerator
  • Venture Investor
    Undisclosed

Trending on Xconomy